Metabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment.
Acylcarnitines
antidepressant
fatty acid oxidation
major depressive disorder
major depressive episode
mitochondria
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
25 May 2023
25 May 2023
Historique:
medline:
25
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
aheadofprint
Résumé
Major depression is associated with changes in plasma L-carnitine and acetyl-L-carnitine. But its association with acylcarnitines remains unclear. The aim of this study was to assess metabolomic profiles of 38 acylcarnitines in patients with major depression before and after treatment compared to healthy controls (HCs). Metabolomic profiles of 38 plasma short-, medium-, and long-chain acylcarnitines were performed by liquid chromatography-mass spectrometry in 893 HCs from the VARIETE cohort and 460 depressed patients from the METADAP cohort before and after 6 months of antidepressant treatment. As compared to HCs, depressed patients had lower levels of medium- and long-chain acylcarnitines. After 6 months of treatment, increased levels of medium- and long-chain acyl-carnitines were observed that no longer differed from those of controls. Accordingly, several medium- and long-chain acylcarnitines were negatively correlated with depression severity. These medium- and long-chain acylcarnitine dysregulations argue for mitochondrial dysfunction through fatty acid
Sections du résumé
BACKGROUND
BACKGROUND
Major depression is associated with changes in plasma L-carnitine and acetyl-L-carnitine. But its association with acylcarnitines remains unclear. The aim of this study was to assess metabolomic profiles of 38 acylcarnitines in patients with major depression before and after treatment compared to healthy controls (HCs).
METHODS
METHODS
Metabolomic profiles of 38 plasma short-, medium-, and long-chain acylcarnitines were performed by liquid chromatography-mass spectrometry in 893 HCs from the VARIETE cohort and 460 depressed patients from the METADAP cohort before and after 6 months of antidepressant treatment.
RESULTS
RESULTS
As compared to HCs, depressed patients had lower levels of medium- and long-chain acylcarnitines. After 6 months of treatment, increased levels of medium- and long-chain acyl-carnitines were observed that no longer differed from those of controls. Accordingly, several medium- and long-chain acylcarnitines were negatively correlated with depression severity.
CONCLUSIONS
CONCLUSIONS
These medium- and long-chain acylcarnitine dysregulations argue for mitochondrial dysfunction through fatty acid
Identifiants
pubmed: 37226550
doi: 10.1017/S003329172300140X
pii: S003329172300140X
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM